<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The stem cell factor (SCF)c-kit receptor interaction plays a critical role in the development and survival of mast cells </plain></SENT>
<SENT sid="1" pm="."><plain>Several studies have also associated c-kit receptor mutations with the human diseases, <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> and <z:hpo ids='HP_0007544'>piebaldism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Overexpression of c-kit has been reported to be associated with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Using peripheral blood mononuclear cells (PBMCs) from 11 patients with indolent <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (category I), <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> with an associated <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> (category II), or aggressive <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (category III); a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> unassociated with <z:hpo ids='HP_0100495'>mastocytosis</z:hpo>, and PBMCs from 13 <z:mpath ids='MPATH_458'>normal</z:mpath> subjects, we examined the level of expression of c-kit <z:chebi fb="2" ids="33699">mRNA</z:chebi> along with other c-kit isoforms to determine if overexpression of the c-kit receptor was associated with <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Using quantitative competitive PCR, c-kit <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels on average were found to be statistically elevated in the five patients with <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> with an associated <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> and in the patient with aggressive <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> as compared with controls, but not elevated in patients with indolent <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The relative <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression for the two c-kit isoforms was not significantly different in the <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> patients compared with controls </plain></SENT>
<SENT sid="6" pm="."><plain>This demonstration of the overexpression of c-kit <z:chebi fb="2" ids="33699">mRNA</z:chebi> in <z:hpo ids='HP_0100495'>mastocytosis</z:hpo>, and particularly those patients with clinical evidence of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, adds evidence to support the conclusion that <z:hpo ids='HP_0100495'>mastocytosis</z:hpo>, at least in some patients, is a feature of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>; and suggests that determination of c-kit <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in PBMCs may provide an additional approach to assessing prognosis </plain></SENT>
</text></document>